25 related articles for article (PubMed ID: 9042663)
1. Apoptosis and proliferation (PCNA labelling) in CML--a comparative immunohistological study on bone marrow biopsies following interferon and busulfan therapy.
Thiele J; Zirbes TK; Lorenzen J; Kvasnicka HM; Dresbach S; Manich B; Leder LD; Niederle N; Diehl V; Fischer R
J Pathol; 1997 Mar; 181(3):316-22. PubMed ID: 9155719
[TBL] [Abstract][Full Text] [Related]
2. Therapy-related changes of CD20+ and CD45RO+ lymphocyte subsets in chronic myeloid leukemia (CML): an immunohistochemical and morphometric study on sequential trephine biopsies of the bone marrow.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Cvetanovska G; Blum N; Schaefer HE
Mod Pathol; 2000 Aug; 13(8):888-96. PubMed ID: 10955456
[TBL] [Abstract][Full Text] [Related]
3. Interferon therapy, but not busulfan restores normal-sized megakaryopoiesis in CML--a comparative histo- and immunomorphometric study.
Thiele J; Zirbes T; Kvasnicka HM; Niederle N; Dammasch J; Schmidt M; Windecker R; Leder LD; Diehl V; Fischer R
Anal Cell Pathol; 1996 Jun; 11(1):31-42. PubMed ID: 8844103
[TBL] [Abstract][Full Text] [Related]
4. Effect of interferon therapy on bone marrow morphology in chronic myeloid leukemia: a cytochemical and immunohistochemical study of trephine biopsies.
Thiele J; Zirbes TK; Kvasnicka HM; Lorenzen J; Niederle N; Leder LD; Fischer R
J Interferon Cytokine Res; 1996 Mar; 16(3):217-24. PubMed ID: 8697144
[TBL] [Abstract][Full Text] [Related]
5. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Bundschuh S; Biermann T; Roessler G; Wasmus M; Diehl V; Zankovich R; Schaefer HE
Am J Clin Pathol; 2000 Jul; 114(1):57-65. PubMed ID: 10884800
[TBL] [Abstract][Full Text] [Related]
6. Effects of interferon treatment on the macrophage population in the bone marrow of patients with Ph1+-CML.
Thiele J; Kvasnicka HM; Zirbes TK; Baldus SE; Djuren O; Lienhard H; Lorenzen J; Leder LD; Niederle N; Fischer R
Hematopathol Mol Hematol; 1996; 10(4):201-12. PubMed ID: 9042663
[TBL] [Abstract][Full Text] [Related]
7. Interferon alpha in the treatment of chronic myelogenous leukemia.
Robak T
Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313
[TBL] [Abstract][Full Text] [Related]
8. [Chronic myelogenous leukemia with long-term hypoplasia induced by alpha-interferon and hydroxyurea].
Motomura S; Sakai R; Tomita N; Fujimaki K; Hattori M; Fujisawa S; Mohri H; Takahashi N; Maruta A; Kodama F; Okubo T
Rinsho Ketsueki; 1998 Apr; 39(4):302-7. PubMed ID: 9597898
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukemia.
Thiele J; Kvasnicka HM
Leuk Lymphoma; 2001; 42(5):855-62. PubMed ID: 11697640
[TBL] [Abstract][Full Text] [Related]
10. [Interferon and so-called interferon inducers].
Havemann K
Wien Klin Wochenschr; 1973 Jun; 85(26):461-6. PubMed ID: 4577809
[No Abstract] [Full Text] [Related]
11. Pharmacokinetic and pharmacological aspects of interferon therapy in man.
Billiau A
Acta Microbiol Acad Sci Hung; 1981; 28(3):257-62. PubMed ID: 6171139
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics and side effects of interferon in man.
Merigan TC
Tex Rep Biol Med; 1977; 35():541-7. PubMed ID: 358475
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
